Allergy & Immunology Doctors in Honolulu, HI Accepting Medicare

7 Allergy & Immunology doctors found. Showing 1 - 7

Marina Ostroukhova, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1329 Lusitana St Ste 603, Honolulu, HI 96813 Phone: 808-521-2712    Fax: 808-537-5823

Dr. Karla Lowe Davis, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: Department Of Medicine- Allergy/immunology, 1 Jarrett White Rd, Honolulu, HI 96859 Phone: 808-433-6334

Dr. Victoria A Wang, M.D. Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 321 N Kuakini St, Suite #603, Honolulu, HI 96817 Phone: 808-526-9702    Fax: 808-526-3121

Dr. Abigail Sutima Harada, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1380 Lusitana St Ste 604, Honolulu, HI 96813 Phone: 808-523-2020    Fax: 808-523-2030

Dr. George J Chu, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 1329 Lusitana St, 102, Honolulu, HI 96813 Phone: 808-532-1311    Fax: 808-536-2224

Dr. Matthew S Lau, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1010 Pensacola St, Honolulu, HI 96814 Phone: 808-432-2000

Dr. Richard Etsuo Ando Jr., MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 405 N Kuakini St, Suite 903, Honolulu, HI 96817 Phone: 808-538-1915

News Archive

Mobile incinerator units can help dispose human remains at disaster sites

Human cremation is not at the top of most people's conversation starters and unless people have experienced bereavement they probably don't give the process a thought. It is a fact that some councils are running out of space for burials in urban cemeteries so cremation is the most common alternative.

Vaccine for deadly RSV could be on the way, scientists say

A vaccine for the common and sometimes deadly RSV (respiratory syncytial virus) has been elusive, but scientists say a new discovery puts them much closer to success.

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

Researchers identify new mechanism associated with p53 mutation

More than half of cancer cases worldwide are associated with genetic mutations in p53, the protein responsible for protecting DNA from changes that can lead to cancer.

Read more Medical News

› Verified 8 days ago